| Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients MS Minot-This, P Boudou-Rouquette, A Jouinot, S De Percin, ... Pharmaceutics 14 (6), 1224, 2022 | 5 | 2022 |
| New approval: Trastuzumab-deruxtecan for metastatic breast cancer HER2 MS Minot-This, A Bellesoeur Bulletin du cancer 108 (9), 783-784, 2021 | 3 | 2021 |
| Nouvelle AMM: trastuzumab-deruxtecan–Cancer du sein HER2+ métastatique MS Minot-This, A Bellesoeur Bulletin du Cancer 108 (9), 783-784, 2021 | 1 | 2021 |
| New approval: Atezolizumab and bevacizumab for first line of unresecable hepatocellular carcinoma MS Minot-This, J Edeline Bulletin du cancer 108 (2), 139-140, 2021 | 1 | 2021 |
| Intracranial hypotension in a breast cancer patient treated with epidural blood patches MS Minot-This, T Grinda, N Epaillard, D Guyon, RE Jawiche, G Garcia, ... CNS oncology 12 (1), CNS94, 2023 | | 2023 |
| Nouvelles AMMs: Pembrolizumab–Cancer du sein triple négatif localisé à haut risque en néoaduvant/adjuvant MS Minot-This, A Deleuze Bulletin du Cancer 109 (10), 988-989, 2022 | | 2022 |
| New drug approval: Pembrolizumab-Neoadjuvant/adjuvant treatment for localized high-risk triple negative breast cancer MS Minot-This, A Deleuze Bulletin du Cancer, S0007-4551 (22) 00273, 2022 | | 2022 |
| Etude pharmacocinétique/pharmacodynamique du pazopanib dans une population de patients atteints de sarcomes des tissus mous et osseux MS Minot-This | | 2021 |
| Atézolizumab et bévacizumab–carcinome hépato-cellulaire non résécable en première ligne MS Minot-This, J Edeline Bulletin du Cancer 108 (2), 139-140, 2021 | | 2021 |
